Recruiting

Amnioband vs. Standard of Care

Sponsor:

SerenaGroup, Inc.

Code:

NCT02609594

Conditions

Venous Leg Ulcers

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Weekly application of Amnioband

Biweekly application of Amnioband

Standard of Care

Study Details

Brief summary:

Lower extremity ulcers pose significant clinical, humanistic and economic burdens on society. Millions of Americans are afflicted with painful, open, draining sores on their lower extremities. These sores are referred to as venous leg ulcerations (VLUs).1-5 Under the best of circumstances these ulcers require weeks or months to heal. Not uncommonly wound care specialists see patients who have suffered for years or faced amputation of the limb as their only option to alleviate the pain.

Standard of care will result in healing in 50% of venous leg ulcers in 12 weeks. However, roughly half of patients suffering from venous ulcers will require advanced therapy. Human amniotic membrane replaces the damaged extracellular matrix characteristic of chronic ulcers. In addition, it contains cytokines that may accelerate healing. In clinical practice and recent studies, Dehydrated Human Amniotic Membrane has appeared to be as effective as bioengineered skin products. This RCT is designed to evaluate Amnioband Dehydrated Human Amniotic Membrane in venous leg ulcers.

Conditions

Venous Leg Ulcers

Study ID

NCT02609594

Start date

Nov, 2015

Status verified date

Sep, 2018

Completion date

Dec, 2018

Anticipated

Primary completion date

Dec, 2018

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. At least 18 years old.
2. Ankle Brachial Pressure Index (ABI) > 0.75 OR SPP > 30 mmHg OR TCOM > 30 mmHg.\*
3. Presence of a venous leg ulcer extending through the full thickness of the skin but not down to muscle, tendon or bone.
4. The largest ulcer will be designated the index ulcer and the only one included in the study. If other ulcerations are present on the same leg they have to be more than 2 cm apart from the index ulcer.
5. Study ulcer (i.e. current episode of ulceration) has been present for greater than one month prior to the initial screening visit, and has failed to respond to documented conservative measures for greater than (1) one month duration and is excluded if it has undergone 12 months of continuous high strength compression therapy over its duration.
6. Study ulcer is a minimum of 2 cm2 and a maximum of 20 cm2 at the randomization visit.
7. The target ulcer has been treated with compression therapy for at least 14 days prior to randomization.
8. Ulcer has a clean, granulating base with minimal adherent slough at the randomization visit.
9. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
10. Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
11. Subject has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria:

1. Study ulcer(s) deemed by the investigator to be caused by a medical condition other than venous insufficiency.
2. Study ulcer exhibits clinical signs and symptoms of infection.
3. Known allergy to the components of the multi-layer compression bandaging, or who cannot tolerate multi-layer compression therapy.
4. Study ulcer, in the opinion of the investigator, is suspicious for cancer should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
5. Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
6. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding Screening.
7. Study ulcer improving greater than 30% during the screening phase if the subject was not in adequate compression 14 days prior to screening.
8. History of drug or alcohol abuse.
9. History of radiation at the ulcer site.
10. Presence of one or more medical conditions, as determined by medical history, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this ulcer healing study.
11. History of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
12. Study ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days
13. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the course of the trial.
14. Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
15. Ulcers on the dorsum of the foot or with more than 50% of the ulcer below the malleolus are excluded.
16. Pregnant or breast feeding.
17. Presence of diabetes with poor metabolic control as documented with a HgA1c > 12.0 within last 90 days
18. Patients with renal dysfunction whose serum creatinine levels are 3.0mg/dl or greater within the last 90 days
19. History of usage of tobacco products within the last 30 days
20. History of Liver disease with active Cirrhosis of the liver

Study Design

Enrollment

240 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Standard of Care

Subjects randomized to this group will receive standard of care (multi-layer compression therapy).

experimental: Weekly application of Amnioband

Weekly application of Amnioband plus standard of care.

experimental: Biweekly application of Amnioband

Biweekly application of Amnioband plus standard of care.

Interventions

Weekly application of Amnioband

Weekly application of Amnioband.

Biweekly application of Amnioband

Biweekly application (every two weeks) of Amnioband.

Standard of Care

Standard of care for this study is weekly multi-layer compression bandaging.

Primary outcome measure

  • Time to complete ulcer closure [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Heather Connell, CCRP

617-383-3979

Locations

Brigham and Women's Hospital Wound Care Center

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Laurie Bayer, PA-C

617-732-8743

Principal Investigator:

Indranil Sinha, MD

Premier Surgical

Recruiting

Brick, New Jersey, United States, 08723

Contacts

Jarrod Kaufman, MD

732-262-1600

The Foot and Ankle Wellness Center

Recruiting

Ford City, Pennsylvania, United States, 16226

Contacts

Matthew Sabo, DPM

724-763-4080

Armstrong County Memorial Hospital

Recruiting

Kittanning, Pennsylvania, United States, 16201

Contacts

Keyur Patel, MD

724-543-8893

SerenaGroup Research Institute

Recruiting

Pittsburgh, Pennsylvania, United States, 15222

Contacts

Thomas Serena, MD

814-688-4000

Martinsville Research Institute

Recruiting

Martinsville, Virginia, United States, 24112

Contacts

Kim Young

540-676-5886

Principal Investigator:

Nathan Young, DPM

More Information

Sponsor

SerenaGroup, Inc.

Last update posted

Sep 7, 2018

Last verified

Sep, 2018

Keywords

  • human amniotic membrane
  • compression therapy
  • venous leg ulcer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by SerenaGroup, Inc. on 2018-09-07.